Healthcare Industry News: Multiple Myeloma
News Release - October 6, 2006
Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell LymphomaStudy results formed basis of supplemental new drug application (sNDA) filing for relapsed mantle cell lymphoma
CAMBRIDGE, Mass., Oct. 6 (HSMN NewsFeed) -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced that the Journal of Clinical Oncology has published the final results of the PINNACLE trial, one of the largest multi-center studies ever done in the setting of relapsed mantle cell lymphoma (MCL). The results demonstrate the potential of VELCADE as treatment for relapsed MCL, an aggressive form of non-Hodgkin's lymphoma (NHL). The study, which provided the major source of data for the sNDA filing for VELCADE in relapsed MCL, was prepublished online in the September 25, 2006 Journal of Clinical Oncology and will run in the October 20, 2006 print issue. VELCADE for relapsed MCL is under Priority Review with the U.S. Food and Drug Administration (FDA) and a decision is expected by December 9, 2006.
"The publication in Journal of Clinical Oncology highlights the potential of VELCADE in the treatment of mantle cell lymphoma," said Deborah Dunsire, M.D., President and CEO, Millennium. "The study, one of several Phase II trials which consistently showed impressive response rates and duration of response, suggests that VELCADE may become a standard component of therapy in this disease."
Results of the study, which was undertaken with Millennium's co-development partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), showed a 33 percent overall response rate and an 8 percent complete response rate. Importantly, the median overall duration of response was 9.2 months, and 13.5 months in patients who achieved a complete response. These results are consistent with those of four investigator-initiated Phase II clinical trials where overall response rates of 30 to 40 percent with single-agent VELCADE were observed.
In this prospective, single-arm study, 155 patients with relapsed or refractory MCL who had received a maximum of two prior therapies, received single-agent VELCADE 1.3mg/m2 twice weekly for two weeks every 21 days for up to one year. Patients achieving complete response, unconfirmed complete response or partial response received a median of 8 treatment cycles, and all patients in the study received a median of 4 cycles. Study results included:
* Overall response rate of 33 percent
* Complete response rate of 8 percent
* Median duration of response of 9.2 months; 13.5 months in patients achieving a complete response
* Median time to progression of 6.2 months
* Median treatment-free interval of 13.8 months in patients achieving a complete response
* Treatment was well tolerated. The most common non-hematologic adverse events were fatigue, gastrointestinal events and peripheral neuropathy. Hematologic toxicities were consistent with those previously seen with VELCADE.
VELCADE currently is approved in the United States for the treatment of Multiple Myeloma (MM) patients who have received at least one prior therapy. To date, over 44,000 MM patients have been treated with VELCADE for MM worldwide, including clinical trials. Earlier this year, Millennium and co-development partner, J&JPRD, initiated a Phase III clinical trial with VELCADE in combination with rituximab in patients with relapsed or refractory follicular and marginal zone lymphoma.
About Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
NHL is the most common hematological cancer, the fifth leading cause of cancer death and the second fastest growing form of cancer in the U.S.(1) The prevalence of NHL is approximately 400,000 patients, 77,000 patients with follicular lymphoma and 10,000 with mantle cell lymphoma. There are approximately 54,000 new cases of NHL diagnosed per year, and 19,000 deaths are attributed to the disease annually(2,3).
MCL is an aggressive, rapidly progressive subtype of NHL, and is not curable with standard treatment. Because there is no generally accepted treatment approach and options are often limited, there is a growing need for new therapies. The average life expectancy for a patient with relapsed MCL is one to two years.
VELCADE is indicated for the treatment of Multiple Myeloma patients who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.
Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE.
In 331 patients who were treated with VELCADE in a Phase III study, the most commonly reported adverse events were asthenic conditions (61 percent), diarrhea (57 percent), nausea (57 percent), constipation (42 percent), peripheral neuropathy (36 percent), vomiting (35 percent), pyrexia (35 percent), thrombocytopenia (35 percent), psychiatric disorders (35 percent), anorexia and appetite decreased (34 percent), parasthesia (27 percent), dysesthesia (27 percent), anemia and headache (26 percent), and cough (21 percent). Fourteen percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (4 percent), neutropenia (2 percent), and hypercalcemia (2 percent). A total of 144 patients on VELCADE (44 percent) reported serious adverse events (SAEs) during the study. The most commonly reported SAEs were pyrexia (6 percent), diarrhea (5 percent), dyspnea and pneumonia (4 percent), and vomiting (3 percent).
VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in more than 75 countries worldwide. VELCADE also is approved in the European Union at first relapse.
For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical Company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Company's website is http://www.millennium.com.
This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN® (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com.
1. 2005, American Cancer Society, Inc., Surveillance Research.
2. SEER, SARGA, and Decision Resources (for growth rate) data.
3. Federico et al., BLOOD 95(3): 783-789; 2000.
Source: Millennium Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.